Mucopolysaccharidosis (MPS) Treatment Market, By Treatment (Enzyme Replacement Therapy and Stem Cell Therapy ), By MPS Type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and Others (MPS-III and MPS-IX)), By End User (Hospitals, Specialty Clinics, and Others),

Mucopolysaccharidosis (MPS) Treatment Market, By Treatment (Enzyme Replacement Therapy and Stem Cell Therapy ), By MPS Type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and Others (MPS-III and MPS-IX)), By End User (Hospitals, Specialty Clinics, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Currently available therapeutics such as Elaprase and Aldurazyme are not able to appropriately address the neurological symptoms and complications of patients suffering from mucopolysaccharidosis (MPS), as these drugs are not capable of crossing blood brain barrier, a key requirement for effective management of mucopolysaccharidosis (MPS) disorder.
The neurological symptoms associated with mucopolysaccharidosis (MPS) disorder are severely disabling. The therapeutics used currently are not able to treat the neurological symptoms, thus a significant proportion of the population is in need of appropriate treatment. This is expected to propel demand for effective therapeutics, which aid in the management of all types of symptoms of mucopolysaccharidosis (MPS). This is expected to drive growth of the MPS treatment market during the forecast period.
Market Dynamics
Market players are focusing on various inorganic growth strategies such as collaborations and partnerships in order to develop no cost testing programs for patients with mucopolysaccharidosis (MPS), which is expected to boost growth of the global mucopolysaccharidosis (MPS) treatment market. For instance, in October 2018, Sanofi Genzyme and PerkinElmer, Inc. collaborated in order to develop a 'Lantern Project', to provide a no-cost testing program for patients in the U.S. and who suffer from specific types of lysosomal storage disorders (LSDs). Therefore, the Latern Project will arrange screening as well as confirmatory DNA testing and phlebotomy services for the patients suspected to be suffering from Gaucher disease, Fabry disease, Pompe disease, mucopolysaccharidosis type I (MPS I) or acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease types A and B.
Key features of the study:
This report provides in-depth analysis of the global mucopolysaccharidosis (MPS) treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global mucopolysaccharidosis (MPS) treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global mucopolysaccharidosis (MPS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global mucopolysaccharidosis (MPS) treatment market

Detailed Segmentation:
Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment:
Enzyme Replacement Therapy
Stem Cell Therapy
Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type:
MPS-I
MPS-II
MPS-IV
MPS-VI
MPS-VII
Others (MPS-III and MPS-IX)
Global Mucopolysaccharidosis (MPS) Treatment Market, By End User:
Hospitals
Specialty Clinics
Others
Global Mucopolysaccharidosis (MPS) Treatment Market, By Region:
North America
By Treatment:
Enzyme Replacement Therapy
Stem Cell Therapy
By MPS Type
MPS-I
MPS-II
MPS-IV
MPS-VI
MPS-VII
Others (MPS-III and MPS-IX)
By End User:
Hospitals
Specialty Clinics
Others
By Country:
U.S.
Canada
Latin America
By Treatment:
Enzyme Replacement Therapy
Stem Cell Therapy
By MPS Type
MPS-I
MPS-II
MPS-IV
MPS-VI
MPS-VII
Others (MPS-III and MPS-IX)
By End User:
Hospitals
Specialty Clinics
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Treatment:
Enzyme Replacement Therapy
Stem Cell Therapy
By MPS Type
MPS-I
MPS-II
MPS-IV
MPS-VI
MPS-VII
Others (MPS-III and MPS-IX)
By End User:
Hospitals
Specialty Clinics
Others
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Treatment:
Enzyme Replacement Therapy
Stem Cell Therapy
By MPS Type
MPS-I
MPS-II
MPS-IV
MPS-VI
MPS-VII
Others (MPS-III and MPS-IX)
By End User:
Hospitals
Specialty Clinics
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Treatment:
Enzyme Replacement Therapy
Stem Cell Therapy
By MPS Type
MPS-I
MPS-II
MPS-IV
MPS-VI
MPS-VII
Others (MPS-III and MPS-IX)
By End User:
Hospitals
Specialty Clinics
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Treatment:
Enzyme Replacement Therapy
Stem Cell Therapy
By MPS Type
MPS-I
MPS-II
MPS-IV
MPS-VI
MPS-VII
Others (MPS-III and MPS-IX)
By End User:
Hospitals
Specialty Clinics
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Takeda Pharmaceutical Company Limited*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
BioMarin Pharmaceuticals, Inc.
Ultragenyx Pharmaceutical Inc.
Sarepta Therapeutics
Abeona Therapeutics Inc.
Eloxx Pharmaceuticals
Esteve
Immusoft Corporation
Inventiva
GC Pharma
JCR Pharmaceuticals Co Ltd.
RegenxBio Inc.
Sangamo Therapeutics, Inc.
Bioasis Technologies Inc.
Paradigm Biopharmaceuticals Ltd.
“*” marked represents similar segmentation in other categories in the respective section.